GSK plc
CIK 0001131399 · LONDON, null · Quarter end: 2026-06-30 · Filed on: 2026-08-13 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$602.2M
2026 Q2
Positions
13
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
97.5%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
CRSP
CRISPR THERAPEUTICS AG
29.2%
Y95308105
WAVE LIFE SCIENCES LTD
17.6%
VIR
VIR BIOTECHNOLOGY INC
14.5%
BNTX
BIONTECH SE
13.7%
IDYA
IDEAYA BIOSCIENCES INC
8.3%
CYTK
CYTOKINETICS INC
4.8%
LYEL
LYELL IMMUNOPHARMA INC
3.5%
SPRO
SPERO THERAPEUTICS INC
3.4%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.